Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aceragen Inc ACGN

Healthcare Biotechnology
Aceragen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and... see more

Recent & Breaking News (NDAQ:ACGN)

Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037

GlobeNewswire September 28, 2020

Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020

GlobeNewswire September 15, 2020

Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire August 4, 2020

Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million

GlobeNewswire July 15, 2020

Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer

GlobeNewswire June 2, 2020

Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders

GlobeNewswire May 1, 2020

Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update

GlobeNewswire April 30, 2020

Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020

GlobeNewswire April 23, 2020

Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma

GlobeNewswire April 21, 2020

Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million

GlobeNewswire April 7, 2020

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

GlobeNewswire March 12, 2020

Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma

GlobeNewswire March 5, 2020

Idera Pharmaceuticals Provides 2020 Update and Outlook

GlobeNewswire January 14, 2020

Idera Pharmaceuticals Announces Private Placement Up To $97.7 Million

GlobeNewswire December 23, 2019

Idera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial Results

GlobeNewswire November 6, 2019

Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037

GlobeNewswire October 21, 2019

Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors

GlobeNewswire September 30, 2019

Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie

GlobeNewswire September 4, 2019

Idera Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference

GlobeNewswire August 30, 2019

Idera Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2019 Financial Results

GlobeNewswire August 8, 2019